JP2021536505A5 - - Google Patents
Info
- Publication number
- JP2021536505A5 JP2021536505A5 JP2021536673A JP2021536673A JP2021536505A5 JP 2021536505 A5 JP2021536505 A5 JP 2021536505A5 JP 2021536673 A JP2021536673 A JP 2021536673A JP 2021536673 A JP2021536673 A JP 2021536673A JP 2021536505 A5 JP2021536505 A5 JP 2021536505A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- solvate
- acceptable salt
- compound according
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862726915P | 2018-09-04 | 2018-09-04 | |
| US62/726,915 | 2018-09-04 | ||
| PCT/US2019/049374 WO2020051153A1 (en) | 2018-09-04 | 2019-09-03 | Muscarinic acetylcholine m1 receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021536505A JP2021536505A (ja) | 2021-12-27 |
| JP2021536505A5 true JP2021536505A5 (https=) | 2022-09-01 |
| JP7460264B2 JP7460264B2 (ja) | 2024-04-02 |
Family
ID=69721873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536673A Active JP7460264B2 (ja) | 2018-09-04 | 2019-09-03 | ムスカリン性アセチルコリンｍ１受容体アンタゴニスト |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12054487B2 (https=) |
| EP (1) | EP3846806A4 (https=) |
| JP (1) | JP7460264B2 (https=) |
| CN (2) | CN112638381B (https=) |
| AU (1) | AU2019336671B2 (https=) |
| CA (1) | CA3108076A1 (https=) |
| WO (1) | WO2020051153A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11512090B2 (en) | 2018-06-11 | 2022-11-29 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
| CA3108076A1 (en) | 2018-09-04 | 2020-03-12 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine m1 receptor antagonists |
| IL326597A (en) * | 2019-10-07 | 2026-04-01 | Contineum Therapeutics Inc | Muscarinic M1 acetylcholine receptor antagonists |
| US11752149B2 (en) | 2019-12-02 | 2023-09-12 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
| KR20240012534A (ko) * | 2021-05-21 | 2024-01-29 | 청두 바이위 파머수티컬 씨오., 엘티디 | 피페라진 유도체 및 이의 의학적 용도 |
| AR126196A1 (es) * | 2021-06-23 | 2023-09-27 | Blueprint Medicines Corp | Proceso para preparar inhibidores de egfr |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4803203A (en) | 1986-11-05 | 1989-02-07 | Warner-Lambert Company | Phenyl and heterocyclic piperazinyl alkoxy-benzheterocyclic compounds as antipsychotic agents |
| US4873331A (en) | 1988-12-09 | 1989-10-10 | American Home Products Corporation | Noradamantyl-carboxylic acid piperazinoalkyl esters |
| US5089497A (en) | 1990-09-20 | 1992-02-18 | Warner-Lambert Company | Substituted piperazines as central nervous system agents |
| ES2161377T3 (es) * | 1995-12-21 | 2001-12-01 | Pfizer | Derivados de octahidro-pirrolo(1,2-a)-pirazina 2,7-sustituidos. |
| US7071335B2 (en) | 2002-02-01 | 2006-07-04 | Euro-Celtique S.A. | 2-pyridinyl-1-piperazine therapeutic agents useful for treating pain |
| WO2004073639A2 (en) | 2003-02-19 | 2004-09-02 | Merck & Co. Inc. | Treatment of psychosis with a muscarinic m1 receptor ectopic activator |
| US8008302B2 (en) | 2004-07-26 | 2011-08-30 | Merck Serono Sa | N-hydroxyamide derivatives and use thereof |
| KR20080070876A (ko) | 2005-12-01 | 2008-07-31 | 쉐링 코포레이션 | 염증 질환 및 미생물 질병 치료용 조성물 |
| US20090156465A1 (en) | 2005-12-30 | 2009-06-18 | Sattigeri Jitendra A | Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors |
| WO2012020567A1 (en) | 2010-08-09 | 2012-02-16 | Raqualia Pharma Inc. | Acyl piperazine derivatives as ttx-s blockers |
| UY34349A (es) | 2011-09-29 | 2013-04-05 | Abb Vie Inc | OCTAHIDROPIRROLO[1,2-a]PIRAZINA SULFONAMIDAS SUSTITUIDAS COMO BLOQUEADORES DE CANALES DE CALCIO |
| US9586964B2 (en) | 2011-10-28 | 2017-03-07 | Vanderbilt University | Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M1 |
| US8697888B2 (en) | 2012-01-06 | 2014-04-15 | Vanderbilt University | Substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs as antagonists of muscarinic acetylcholine M1 receptors |
| US20130289019A1 (en) | 2012-04-26 | 2013-10-31 | Amazing Grace, Inc. | Methods of treating behaviorial and/or mental disorders |
| CN107098899B (zh) | 2012-09-18 | 2019-09-06 | 赫普泰雅治疗有限公司 | 作为毒蕈碱的m1受体激动剂的二环氮杂化合物 |
| BR112018008630A2 (pt) | 2015-11-06 | 2018-10-30 | Neurocrine Biosciences Inc | derivados de n-[2-(1-benzilpiperidin-4-il)etil]-4-(pirazin-2-il)-piperazina-1-carboxamida, seus usos, composição farmacêutica |
| WO2018085803A1 (en) | 2016-11-07 | 2018-05-11 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| WO2018089433A1 (en) | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PHENYL mTORC INHIBITORS AND USES THEREOF |
| US11485740B2 (en) | 2018-02-15 | 2022-11-01 | Boehringer Ingelheim International Gmbh | Inhibitors of TRPC6 |
| FI3788040T3 (fi) | 2018-04-30 | 2023-06-13 | Ribon Therapeutics Inc | Pyridatsinoneja parp7-inhibiittoreina |
| US11512090B2 (en) | 2018-06-11 | 2022-11-29 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
| CA3108076A1 (en) | 2018-09-04 | 2020-03-12 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine m1 receptor antagonists |
| IL326597A (en) | 2019-10-07 | 2026-04-01 | Contineum Therapeutics Inc | Muscarinic M1 acetylcholine receptor antagonists |
| US11752149B2 (en) | 2019-12-02 | 2023-09-12 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
-
2019
- 2019-09-03 CA CA3108076A patent/CA3108076A1/en active Pending
- 2019-09-03 JP JP2021536673A patent/JP7460264B2/ja active Active
- 2019-09-03 CN CN201980057628.6A patent/CN112638381B/zh active Active
- 2019-09-03 US US17/267,677 patent/US12054487B2/en active Active
- 2019-09-03 CN CN202411263115.XA patent/CN119112895A/zh active Pending
- 2019-09-03 EP EP19857624.1A patent/EP3846806A4/en active Pending
- 2019-09-03 WO PCT/US2019/049374 patent/WO2020051153A1/en not_active Ceased
- 2019-09-03 AU AU2019336671A patent/AU2019336671B2/en active Active
-
2024
- 2024-06-18 US US18/747,272 patent/US20250026758A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021536505A5 (https=) | ||
| JP7555327B2 (ja) | Ｎｌｒｐ３インフラマソーム阻害剤 | |
| US11702422B2 (en) | Imidazopyridazines as modulators of IL-17 | |
| JP6505013B2 (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| TWI662023B (zh) | 治療活性化合物及其使用方法（二） | |
| US7550481B2 (en) | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of Alzheimer's disease | |
| JP5693814B2 (ja) | 新規のヒスタミンｈ３−受容体リガンドおよびそれらの治療的応用 | |
| JP6321825B2 (ja) | 神経形成を刺激することができるｎ−フェニル−ラクタム誘導体及び神経障害の処置におけるそれらの使用 | |
| JP2019034943A (ja) | Ｈｂｖ感染に対する新規抗ウイルス剤 | |
| TW201331177A (zh) | 治療活性組合物及其使用方法 | |
| JP2011512359A (ja) | プロスタグランジンｄ２受容体のアンタゴニストとしての環式ジアリールエーテル化合物 | |
| KR20190004742A (ko) | 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법 | |
| KR20230035049A (ko) | 화합물, 조성물 및 방법 | |
| JP2021528405A (ja) | ＲＯＲγｔのモジュレータとしてのアミド置換チアゾール | |
| JP2020518571A5 (https=) | ||
| JP7158464B2 (ja) | カリウムチャネル阻害剤としての置換ベンゾイミダゾール | |
| AU2023357827A1 (en) | Cyclopentane compound | |
| JP2013541569A (ja) | ジヒドロオキサゾール−２−アミン誘導体 | |
| JP2021512910A5 (https=) | ||
| RU2011139287A (ru) | Оксииндольные производные, обладающие агонистической активностью в отношении мотилинового рецептора | |
| CN101602730B (zh) | 取代的咪唑衍生物 | |
| JP2014001142A (ja) | シクロアルカン化合物 | |
| WO2017008681A1 (zh) | 酰胺类衍生物、其制备方法及其在医药上的用途 | |
| TW202539691A (zh) | ＳＰＰＬ２ａ抑制劑 | |
| JP2022151801A (ja) | 複素環化合物 |